Hourglass Capital, LLC Abb Vie Inc. Transaction History

Hourglass Capital, LLC

$359 Million
Q3 2024

A detailed history of Hourglass Capital, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Hourglass Capital, LLC holds 49,503 shares of ABBV stock, worth $8.69 Million. This represents 2.73% of its overall portfolio holdings.

Number of Shares

49,503

Previous 80,668 38.63%

Holding current value

$8.69 Million

Previous $13.8 Million 29.35%

% of portfolio

2.73%

Previous 4.11%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 06, 2024	SELL	$163.84 - $199.33 $5.11 Million - $6.21 Million	-31,165 Reduced 38.63%	49,503 $9.78 Million
Q2 2024 Aug 05, 2024	SELL	$154.79 - $180.76 $303,388 - $354,289	-1,960 Reduced 2.37%	80,668 $13.8 Million
Q1 2024 Apr 26, 2024	SELL	$159.82 - $182.1 $228,222 - $260,038	-1,428 Reduced 1.7%	82,628 $15 Million
Q4 2023 Feb 09, 2024	SELL	$137.6 - $154.97 $71,552 - $80,584	-520 Reduced 0.61%	84,056 $13 Million
Q3 2023 Nov 02, 2023	SELL	$133.59 - $154.65 $62,119 - $71,912	-465 Reduced 0.55%	84,576 $12.6 Million
Q2 2023 Aug 01, 2023	SELL	$132.51 - $164.9 $58,966 - $73,380	-445 Reduced 0.52%	85,041 $11.5 Million
Q1 2023 Apr 28, 2023	SELL	$144.61 - $166.54 $462,896 - $533,094	-3,201 Reduced 3.61%	85,486 $13.6 Million
Q4 2022 Feb 09, 2023	SELL	$138.31 - $165.87 $127,936 - $153,429	-925 Reduced 1.03%	88,687 $14.3 Million
Q3 2022 Nov 07, 2022	BUY	$134.21 - $153.93 $56,368 - $64,650	420 Added 0.47%	89,612 $12 Million
Q2 2022 Aug 05, 2022	BUY	$137.62 - $174.96 $112,986 - $143,642	821 Added 0.93%	89,192 $13.7 Million
Q1 2022 May 04, 2022	BUY	$131.98 - $163.75 $210,508 - $261,181	1,595 Added 1.84%	88,371 $14.3 Million
Q4 2021 Feb 11, 2022	SELL	$107.43 - $135.93 $2.25 Million - $2.85 Million	-20,980 Reduced 19.47%	86,776 $11.7 Million
Q3 2021 Nov 12, 2021	SELL	$106.4 - $120.78 $463,904 - $526,600	-4,360 Reduced 3.89%	107,756 $11.6 Million
Q2 2021 Aug 12, 2021	BUY	$105.21 - $117.21 $99,423 - $110,763	945 Added 0.85%	112,116 $12.6 Million
Q1 2021 May 06, 2021	BUY	$102.3 - $112.62 $678,249 - $746,670	6,630 Added 6.34%	111,171 $12 Million
Q4 2020 Feb 10, 2021	SELL	$80.49 - $108.67 $329,204 - $444,460	-4,090 Reduced 3.77%	104,541 $11.2 Million
Q3 2020 Nov 12, 2020	BUY	$85.91 - $100.83 $146,906 - $172,419	1,710 Added 1.6%	108,631 $9.52 Million
Q2 2020 Aug 11, 2020	BUY	$73.37 - $98.18 $2.65 Million - $3.54 Million	36,076 Added 50.92%	106,921 $10.5 Million
Q1 2020 May 07, 2020	BUY	$64.5 - $97.79 $67,725 - $102,679	1,050 Added 1.5%	70,845 $5.4 Million
Q4 2019 Feb 12, 2020	SELL	$72.13 - $90.25 $157,964 - $197,647	-2,190 Reduced 3.04%	69,795 $6.18 Million
Q3 2019 Nov 06, 2019	BUY	$62.98 - $75.72 $59,831 - $71,934	950 Added 1.34%	71,985 $5.45 Million
Q2 2019 Aug 12, 2019	BUY	$65.7 - $83.98 $1.92 Million - $2.45 Million	29,173 Added 69.69%	71,035 $5.17 Million
Q1 2019 May 03, 2019	SELL	$77.14 - $90.79 $299,303 - $352,265	-3,880 Reduced 8.48%	41,862 $3.37 Million
Q4 2018 Feb 08, 2019	SELL	$77.85 - $96.01 $16,192 - $19,970	-208 Reduced 0.45%	45,742 $4.22 Million
Q3 2018 Nov 09, 2018	BUY	$88.91 - $98.84 $31,118 - $34,594	350 Added 0.77%	45,950 $4.35 Million
Q2 2018 Aug 10, 2018	SELL	$89.78 - $106.23 $383,360 - $453,602	-4,270 Reduced 8.56%	45,600 $4.23 Million
Q1 2018 May 07, 2018	SELL	$92.01 - $123.21 $3.28 Million - $4.4 Million	-35,700 Reduced 41.72%	49,870 $4.72 Million
Q4 2017 Feb 08, 2018	SELL	$89.56 - $98.21 $117,323 - $128,655	-1,310 Reduced 1.51%	85,570 $8.28 Million
Q3 2017 Nov 13, 2017	BUY	$69.85 - $89.22 $6.07 Million - $7.75 Million	86,880	86,880 $7.72 Million

Others Institutions Holding ABBV

# of Institutions

3,853

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $310B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hourglass Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Hourglass Capital, LLC with notifications on news.

Account

Hourglass Capital, LLC Abb Vie Inc. Transaction History